Q32 Bio (QTTB) News Today $1.51 -0.05 (-3.21%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataApril 30, 2025 | prnewswire.comQ32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Consensus PT from BrokeragesApril 27, 2025 | americanbankingnews.comLeerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)April 18, 2025 | markets.businessinsider.comQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataApril 16, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)March 12, 2025 | markets.businessinsider.comQ32 Bio price target lowered to $15 from $16 at Wells FargoMarch 12, 2025 | markets.businessinsider.comQ32 Bio Reports Promising Trial Results and FinancialsMarch 12, 2025 | tipranks.comQ32 Bio: Q4 Earnings SnapshotMarch 11, 2025 | sfgate.comQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdateMarch 11, 2025 | prnewswire.comQ32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibartMarch 10, 2025 | markets.businessinsider.comQ32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingMarch 8, 2025 | prnewswire.comQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual MeetingFebruary 28, 2025 | prnewswire.comQ32 Bio to Participate in Upcoming March Investor ConferencesFebruary 26, 2025 | prnewswire.comPiper Sandler Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comBMO Capital Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comQ32 Bio (NASDAQ:QTTB) Stock Quotes, Forecast and News SummaryFebruary 12, 2025 | benzinga.comPiper Sandler cuts Q32 Bio stock rating to neutral, slashes targetFebruary 11, 2025 | msn.comQ32 Bio downgraded to Neutral from Overweight at Piper SandlerFebruary 11, 2025 | markets.businessinsider.comQ32 Bio downgraded to Market Perform from Outperform at BMO CapitalFebruary 11, 2025 | markets.businessinsider.comBMO cuts Q32 Bio stock rating, slashes price target to $3February 11, 2025 | msn.comQ32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia AreataFebruary 10, 2025 | prnewswire.comQ32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | prnewswire.comQTTB stock touches 52-week low at $2.95 amid market challengesFebruary 3, 2025 | msn.comFY2025 EPS Estimates for Q32 Bio Raised by Leerink PartnrsQ32 Bio Inc. (NASDAQ:QTTB - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Q32 Bio in a research report issued to clients and investors on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts thatDecember 13, 2024 | marketbeat.comGuggenheim Downgrades Q32 Bio (QTTB)December 13, 2024 | msn.comLeerink Partnrs Downgrades Q32 Bio (NASDAQ:QTTB) to HoldLeerink Partnrs cut shares of Q32 Bio from a "strong-buy" rating to a "hold" rating in a report on Wednesday.December 12, 2024 | marketbeat.comWells Fargo Downgrades Q32 Bio (QTTB)December 12, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Stock, Short Interest ReportDecember 11, 2024 | benzinga.comInvestors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia TreatmentDecember 11, 2024 | yahoo.comPiper Sandler Reaffirms Their Buy Rating on Q32 Bio (QTTB)December 11, 2024 | markets.businessinsider.comLeerink Partners Downgrades Q32 Bio (QTTB)December 11, 2024 | msn.comQ32 Bio (QTTB) Receives a Buy from OppenheimerDecember 11, 2024 | markets.businessinsider.comWhy Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?December 11, 2024 | benzinga.comQ32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test ResultsDecember 11, 2024 | marketwatch.comQ32 Bio: Oppenheimer slashes price target on mixed trial resultsDecember 11, 2024 | msn.comQ32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence DropsDecember 11, 2024 | msn.comQ32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia TreatmentDecember 11, 2024 | investors.comOppenheimer Has Lowered Expectations for Q32 Bio (NASDAQ:QTTB) Stock PriceOppenheimer lowered their target price on shares of Q32 Bio from $80.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday.December 11, 2024 | marketbeat.comLeerink Partners Reaffirms "Market Perform" Rating for Q32 Bio (NASDAQ:QTTB)Leerink Partners reissued a "market perform" rating and issued a $9.00 target price (down from $68.00) on shares of Q32 Bio in a report on Wednesday.December 11, 2024 | marketbeat.comRaymond James Reaffirms Outperform Rating for Q32 Bio (NASDAQ:QTTB)Raymond James reissued an "outperform" rating and set a $22.00 price target (down previously from $90.00) on shares of Q32 Bio in a report on Wednesday.December 11, 2024 | marketbeat.comWells Fargo & Company Reaffirms Equal Weight Rating for Q32 Bio (NASDAQ:QTTB)Wells Fargo & Company reissued an "equal weight" rating and issued a $16.00 price objective (down from $95.00) on shares of Q32 Bio in a research note on Wednesday.December 11, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Price Target Lowered to $20.00 at Piper SandlerPiper Sandler dropped their price objective on Q32 Bio from $85.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday.December 11, 2024 | marketbeat.comFmr LLC Purchases 246,664 Shares of Q32 Bio Inc. (NASDAQ:QTTB)Fmr LLC boosted its position in shares of Q32 Bio Inc. (NASDAQ:QTTB - Free Report) by 137.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 426,302 shares of the company's stock after buying an additional 246,664 shares duringDecember 11, 2024 | marketbeat.comQ32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development ProgramDecember 10, 2024 | prnewswire.comPoint72 Asset Management L.P. Purchases New Shares in Q32 Bio Inc. (NASDAQ:QTTB)Point72 Asset Management L.P. acquired a new stake in Q32 Bio Inc. (NASDAQ:QTTB - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 76,685 shares of the company's stock, valued at approximately $3,422,000. Point72 Asset Management L.December 9, 2024 | marketbeat.comBMO Capital Initiates Coverage of Q32 Bio (QTTB) with Outperform RecommendationDecember 6, 2024 | msn.comQ32 Bio (NASDAQ:QTTB) Coverage Initiated by Analysts at BMO Capital MarketsBMO Capital Markets assumed coverage on Q32 Bio in a report on Friday. They set an "outperform" rating and a $64.00 target price for the company.December 6, 2024 | marketbeat.comQ32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%December 4, 2024 | finance.yahoo.comQ32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Buy" from AnalystsQ32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The averagNovember 25, 2024 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 0.9% - Here's WhyQ32 Bio (NASDAQ:QTTB) Stock Price Down 0.9% - What's Next?November 22, 2024 | marketbeat.com Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address QTTB Media Mentions By Week QTTB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QTTB News Sentiment▼0.500.69▲Average Medical News Sentiment QTTB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QTTB Articles This Week▼21▲QTTB Articles Average Week Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies InflaRx News Today Instil Bio News Today Seres Therapeutics News Today Alpha Cognition News Today CervoMed News Today ESSA Pharma News Today Invivyd News Today IGM Biosciences News Today Aerovate Therapeutics News Today Unicycive Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QTTB) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QTTB Stock Free QTTB Stock Alerts